https://www.prlog.org/12846049-galaxy-diagnostics-launches-the-most-sensitive-test-available-for-direct-detection-of-lyme-disease.html

Galaxy Diagnostics Launches the Most Sensitive Test Available for Direct Detection of Lyme Disease

Science Leader in the Testing of Flea and Tick Borne Illness Introduces the Nanotrap® Urine Test for Lyme Borreliosis

By: Galaxy Diagnostics, Inc.123

Nanotrap Most Sensitive Test for Lyme Borreliosis

Nanotrap Most Sensitive Test for Lyme Borreliosis

DURHAM, N.C. – Nov. 10, 2020 – PRLog — Galaxy Diagnostics, Inc., the science leader in sample enrichment powered testing solutions for elusive flea and tick-borne pathogens, today announced the launch of the Nanotrap® Urine Test for Lyme Borreliosis.  This urine-based Lyme antigen test provides the most sensitive direct detection of Borrelia burgdorferi infection at all stages of the disease.  The test provides advantages antibody testing does not, namely:

  • Identifies positive cases missed by CDC-recommended Two-Tiered Testing (TTT)
  • Reduces concern for false positive results via direct detection of OspA proteins
  • Uses easy-to-collect urine sample

The revolutionary test greatly increases the likelihood of Lyme disease confirmation via innovative Nanotrap® technology developed by Ceres Nanosciences. Nanotrap® particles capture and concentrate low abundance Outer surface protein A (OspA) in urine samples confirmed by a highly sensitive Western blot.

Published data shows that the Nanotrap Urine Test is very effective for confirmation of early stage Lyme borreliosis in patients with EM rashes (24/24). Galaxy validation data (unpublished) shows that the Nanotrap® Urine Test will often confirm active infection in patients with negative TTT results. Further research is needed to confirm clinical utility for other presentations of Lyme borreliosis, including Lyme arthritis, Lyme carditis, and neuroborreliosis.

“The addition of the Nanotrap® test aligns with our mission to bring the most scientifically advanced sample enrichment technologies and diagnostic advances to the forefront of flea and tick borne disease”, said Galaxy CEO Amanda Elam. “Lyme disease is the fastest growing tick-borne illness in the United States. We are committed to improving the standard of care around detection of these elusive, low abundance pathogens to ensure better patient care for millions globally.”

Galaxy advocates for a new standard of care in Lyme Borreliosis testing and recommends a combination diagnostic protocol with Nanotrap® Urine test to confirm active infection and the CDC recommended TTT to detect the presence of antibodies.

You can order here and learn more at galaxydx.com.

About Galaxy Diagnostics

Galaxy Diagnostics is a privately held medical laboratory located in Research Triangle Park offering the only testing solutions powered by revolutionary sample enrichment technologies for elusive flea and tick borne pathogens. The company’s mission is to “Go Beyond” the limits of conventional detection by driving scientific innovation, creating new clinical knowledge through research and publication, and providing medical education and excellent customer support to healthcare providers, veterinarians, patients, and research customers in this important area of emerging infectious disease.

About Ceres Nanosciences

Ceres Nanosciences is a privately held company, located in Northern Virginia, focused on incorporating its novel Nanotrap® particle technology into a range of diagnostic products and workflows. The Nanotrap® particle technology can improve diagnostic testing by capturing, concentrating, and preserving low abundance analytes from biological samples. The Nanotrap® particle technology was developed with support from the National Institutes of Health (NIH), the Defense Advanced Research Projects Agency (DARPA), the Bill and Melinda Gates Foundation, Schmidt Futures, the Defense Threat Reduction Agency (DTRA), and the Commonwealth of Virginia.

Contact
James Rebenski
***@galaxydx.com

Photos:
https://www.prlog.org/12846049/1
https://www.prlog.org/12846049/2
https://www.prlog.org/12846049/3

_____________________

**Comment**

According to Dr. Shor, this “urine-based antigen test,” based on the OspA protein, is 100% sensitive for acute cases with EM rash (24/24 patients with EM rash tested positive). Please remember that while appearing successful for acute Lyme, this is a small study group. Also, having the EM rash is DIAGNOSTIC for Lyme – i.e. no testing even required.

It is far less effective for those who are chronically infected. It was positive for 42% out of 100 chronically ill patients.

I believe I heard Dr. Klinghardt recommend rolfing (deep tissue massage) before taking this test to force the organisms out in the blood where they can be excreted and picked up on this urine test.

To watch Dr. Shor’s presentation:

http://  Approx. 1 hour 20 Min

May 24, 2017

NatCapLyme Presentation

Diagnosing people early is critical as doctors, despite knowing this complex illness can become very severe and more difficult to treat if left untreated, continue to take a ‘wait and see’ approach. They continue to rely upon faulty testing that misses anywhere from 70-86% of cases, and often wait for test results before treating – dooming thousands of patients to a life-time of suffering. This test will hopefully help these early cases; however, it will not be as effective for the chronically infected – nor help with those who are coinfected.

Diagnosing tick-borne illness has always been a clinical diagnosis.

Time for doctors to become educated instead of lazily relying upon faulty testing.